Fecha de publicación
Nº de solicitud
|1.||WO||WO/2011/102967 - AUDIO DECODER AND DECODING METHOD USING EFFICIENT DOWNMIXING||25.08.2011||
|PCT/US2011/023533||DOLBY LABORATORIES LICENSING CORPORATION||THESING, Robin|
A method, an apparatus, a computer readable storage medium configured with instructions for carrying out a method, and logic encoded in one or more computer- readable tangible medium to carry out actions. The method is to decode audio data that includes N.n channels to M.m decoded audio channels, including unpacking metadata and unpacking and decoding frequency domain exponent and mantissa data; determining transform coefficients from the unpacked and decoded frequency domain exponent and mantissa data; inverse transforming the frequency domain data; and in the case M
|2.||WO||WO/2011/033194 - NOVEL METHOD FOR SYNTHESIZING IVABRADINE AND THE ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID||24.03.2011||
|PCT/FR2010/000625||LES LABORATOIRES SERVIER||PEGLION, Jean-Louis|
The invention relates to a method for synthesizing ivabradine of formula (I) and to the addition salts thereof with a pharmaceutically acceptable acid.
|3.||WO||WO/2011/027805 - THERAPEUTIC AGENT FOR MOOD DISORDERS||10.03.2011||
|PCT/JP2010/064988||Kyowa Hakko Kirin Co., Ltd.||YAMADA, Koji|
Disclosed is a therapeutic and/or prophylactic agent for mood disorders, which contains a thiazole derivative represented by general formula (I) (wherein R1 represents an aryl group or the like, and R2 represents a pyridyl group or the like) or a pharmaceutically acceptable salt thereof as an active ingredient.
|4.||WO||WO/2011/027806 - THERAPEUTIC AGENT FOR ANXIETY DISORDERS||10.03.2011||
|PCT/JP2010/064989||Kyowa Hakko Kirin Co., Ltd.||KASE, Junya|
Disclosed is a therapeutic and/or prophylactic agent for anxiety disorders, which contains a thiazole derivative represented by general formula (I) (wherein R1 represents an aryl group or the like, and R2 represents a pyridyl group or the like) or a pharmaceutically acceptable salt thereof as an active ingredient.
|5.||WO||WO/2011/018480 - PHARMACEUTICAL COMPOSITION INCLUDING A DHA ESTER TO BE PARENTERALLY ADMINISTERED||17.02.2011||
|PCT/EP2010/061701||PIERRE FABRE MEDICAMENT||LEVERD, Elie|
The present invention relates to a pharmaceutical composition to be parenterally administered, including submicronic ester particles of docosahexaenoic acid, dispersed in an aqueous phase using a mixture of at least two surfactants selected from among a) at least one polyoxyethylene fatty acid ester and b) at least one phospholipid derivative. The present invention also relates to the method for preparing said pharmaceutical composition.
|6.||WO||WO/2011/017639 - METHODS OF USING C-MET MODULATORS||10.02.2011||
|PCT/US2010/044749||EXELIXIS, INC||AFTAB, Dana T.|
Methods of treating cancer by administering a compound of Formula (I), (Formula I) or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments are described, wherein R1 is halo; R2 is halo; and Q is CH or N.
|7.||WO||WO/2011/014494 - ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF β-AMINO-α- HYDROXY AMIDES||03.02.2011||
|PCT/US2010/043356||SCHERING CORPORATION||TRAVERSE, John|
Processes useful for the preparation of a Compound of Formula I: Formula (I). Intermediates useful for the preparation of the compound of Formula I, and processes useful for preparing said intermediates are disclosed.
|8.||WO||WO/2011/008324 - LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS||20.01.2011||
|PCT/US2010/033245||MEDICIS PHARMACEUTICAL CORPORATION||NORDSIEK, Michael T.|
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1 isobuty 1-1 H-imidazo [4, 5 -c] -quinolin-4-amine or 1 -(2-methylpropyl)- 1 H-imidazo [4,5 -c] quinolin-4-arnme, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration ("FDA"), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration ("FDA") for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
|9.||WO||WO/2011/003737 - USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES||13.01.2011||
|PCT/EP2010/058881||AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.||GUGLIELMOTTI, Angelo|
Use of benzydamine in the treatment of inflammatory diseases, in particular Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and psoriasis, caused by an expression or overexpression of the cytokine subunit p40.
|10.||WO||WO/2011/000930 - L-SERINE TO BE USED AS A DRUG FOR PREVENTING AND/OR TREATING AN INFLAMMATORY RESPONSE OF THE SKIN||06.01.2011||
|PCT/EP2010/059401||PIERRE FABRE DERMO-COSMETIQUE||DECHELETTE, Corinne|
The invention relates to the use of L-serine as a drug for preventing and/or treating an inflammatory response of the skin caused by the overexpression and/or the overactivation of PAR2 receptors.